{
  "id": 106224,
  "name": "GLAXOSMITHKLINE, INC",
  "slug": "glaxosmithkline-inc",
  "state": "DC",
  "description": "Pharmaceutical and Healthcare Company",
  "totalSpending": 2050000,
  "filings": 32,
  "yearlySpending": [
    {
      "year": 2018,
      "income": 320000
    },
    {
      "year": 2019,
      "income": 320000
    },
    {
      "year": 2020,
      "income": 270000
    },
    {
      "year": 2021,
      "income": 240000
    },
    {
      "year": 2022,
      "income": 240000
    },
    {
      "year": 2023,
      "income": 240000
    },
    {
      "year": 2024,
      "income": 180000
    },
    {
      "year": 2025,
      "income": 240000
    }
  ],
  "firms": [
    "BGR GOVERNMENT AFFAIRS"
  ],
  "lobbyists": [
    "ROBERT WOOD",
    "BRENT DEL MONTE",
    "DAVID BOYER",
    "JOHN STONE",
    "MATT HOFFMANN",
    "REMY MASON",
    "ROBB WALTON",
    "DANIEL FARMER",
    "JOEL BAILEY",
    "RAGHAV AGGARWAL",
    "CHRIS KELLY"
  ],
  "issues": [
    "HCR",
    null
  ],
  "sampleDescriptions": [
    "Strategic guidance and counsel on health care related issues to include: healthcare reform, HIV/AIDS, bio-defense, Medicare/Medicaid",
    "Strategic guidance and advocacy on health care related issues to include: healthcare reform, HIV/AIDS, bio-defense, Medicare/Medicaid",
    "Strategic guidance and advocacy on health care related issues to include: healthcare reform, HIV/AIDS, bio-defense, Medicare/Medicaid and FDA"
  ],
  "years": [
    2018,
    2019,
    2020,
    2021,
    2022,
    2023,
    2024,
    2025
  ],
  "growthRate": -25,
  "trajectory": "reducing",
  "yearsActive": 8,
  "avgAnnualSpending": 256250,
  "peakYear": 2018,
  "lobbyistCount": 11,
  "firmCount": 1,
  "issueCount": 1,
  "industry": "healthcare"
}